How Japan regulates regenerative medicine
In Japan, regenerative medicine is not left to general medical practice: it is governed by a dedicated law. This page sets out, in order, the regulatory facts you need before you go.
01A dedicated law
Japan’s Act on the Safety of Regenerative Medicine (再生医療等の安全性の確保等に関する法律, Act No. 85 of 2013) took effect in November 2014. It governs regenerative medicine provided by medical institutions.
Source: Ministry of Health, Labour and Welfare (MHLW), "再生医療・細胞医療・遺伝子治療について" (Regenerative, cell and gene therapy); checked 2026-11
02A provision plan comes first
Before offering regenerative medicine, a medical institution must prepare a “provision plan for regenerative medicine”, have it reviewed by a certified committee for regenerative medicine, and submit it to the Ministry of Health, Labour and Welfare (MHLW) through the “e-再生医療” system.
So the most useful thing to confirm before you go is whether the clinic you are considering has submitted a provision plan for the treatment you want. Send the clinic name to our advisor and we will check whether it has submitted a provision plan.
Source: Ministry of Health, Labour and Welfare (MHLW), "再生医療・細胞医療・遺伝子治療について" (Regenerative, cell and gene therapy); checked 2026-11
03Three classes by risk
The Act sorts regenerative medicine by risk into Class I (high risk), Class II (medium risk) and Class III (low risk). Two kinds of committee carry out the review: a “Specially Certified Committee for Regenerative Medicine”, and a “Certified Committee for Regenerative Medicine” that reviews Class III only.
The table shows how treatments generally map to the classes. The class of a specific treatment is whatever the clinic’s submitted plan states.
| Class | Risk | Generally includes | Review committee |
|---|---|---|---|
| Class I | High risk | iPS cells, ES cells and similar | Specially Certified Committee for Regenerative Medicine |
| Class II | Medium risk | The patient’s own somatic stem cells (e.g. adipose-derived stem cells) | Specially Certified Committee for Regenerative Medicine |
| Class III | Low risk | Somatic cell processing without stem cells (e.g. immune cell therapy); PRP for dental and similar uses mostly falls here | Certified Committee for Regenerative Medicine |
Source: Ministry of Health, Labour and Welfare (MHLW), "再生医療・細胞医療・遺伝子治療について" (Regenerative, cell and gene therapy); MHLW division notice, risk-classification chart; checked 2026-11
04The 2025 amendment covers in vivo gene therapy
On 31 May 2025 the amended Act (Act No. 51 of 2024) took effect, bringing in vivo gene therapy that does not use processed cells under the Act as well.
Source: Ministry of Health, Labour and Welfare (MHLW), "再生医療・細胞医療・遺伝子治療について" (Regenerative, cell and gene therapy); checked 2026-11
05An information and reporting window, 2026
On 2 September 2026 the MHLW opened an information and reporting window for regenerative medicine, which takes reports of illegal practice or safety concerns.
Source: Ministry of Health, Labour and Welfare (MHLW), "再生医療・細胞医療・遺伝子治療について" (Regenerative, cell and gene therapy); checked 2026-11
06First conditional approvals for iPS cell-derived products
On 6 March 2026 the MHLW granted conditional, time-limited (7-year) approval to Sumitomo Pharma’s iPS cell-derived product for Parkinson’s disease (アムシェプリ) and to Cuorips’ product for severe heart failure (リハート). These are the first iPS cell-derived products to be approved.
After conditional approval, post-marketing surveillance of every treated case is still required before full approval can be applied for.
Source: Science Portal (JST), 18 March 2026; Sumitomo Pharma announcement; checked 2026-11